Morgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $94 from $90 and keeps an Overweight rating on the shares after “another strong quarter” in Q3, highlighted by Tryngolza in FCS outperforming again and driving a third guidance raise for the year. The firm expects detailed SHTG data at the upcoming AHA meeting on November 8 to “further strengthen the profile,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $99 from $59 at TD Cowen
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating
- Ionis Pharmaceuticals price target raised to $95 from $80 at Barclays
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth